Literature DB >> 7332734

Correlation between antithyroid effect and serum concentrations of propylthiouracil in patients with hyperthyroidism.

J P Kampmann, J E Mølholm Hansen.   

Abstract

1 Correlation between the kinetics of propylthiouracil and its antithyroid effect was studied in 17 hyperthyroid patients. The serum concentration of propylthiouracil 1 h after an oral dose of 400 mg of hyperthyroid patients. The serum concentration of propylthiouracil 1 h after an oral dose of 400 mg of the drug was used as kinetic parameter as this concentration from the previous study was found to correlate significantly (r = 0.84, P less than 0.01) with the area under the serum concentration-time curve. 2 After 3 weeks of treatment with 200 mg propylthiouracil three times daily the serum concentration of propylthiouracil was correlated to the decrease in various thyroid parameters such as total and free indexes of serum thyroxine, triiodothyronine and reverse triiodothyronine. 3 Significant correlations were found between the serum concentration of propylthiouracil and all the measured thyroid variables except reverse triiodothyronine. The highest degree of correlation was obtained between serum propylthiouracil and the percentage decrease in total and free indexes of triiodothyronine (r = 0.63 and 0.70, respectively, P less than 0.01). 4 It is suggested that a serum concentration of propylthiouracil above 4 to 5 micrograms/ml 1 h after an oral dose of 400 mg of the drug will secure a sufficient and rapid antithyroid effect during continuous therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332734      PMCID: PMC1401968          DOI: 10.1111/j.1365-2125.1981.tb01289.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

1.  Pharmacokinetics of propylthiouracil in man after a single oral dose.

Authors:  D S Sitar; D B Hunninghake
Journal:  J Clin Endocrinol Metab       Date:  1975-01       Impact factor: 5.958

2.  Determination of serum thyroxine. The diagnostic value in thyroid diseases.

Authors:  K Siersbaek-Nielsen
Journal:  Acta Med Scand       Date:  1967-03

3.  The acclumulation of 35 S-antithyroid drugs by the thyroid gland.

Authors:  B Marchant; W D Alexander; J H Lazarus; J Lees; D H Clark
Journal:  J Clin Endocrinol Metab       Date:  1972-05       Impact factor: 5.958

4.  A simple test for selecting the thioamide schedule in thyrotoxicosis.

Authors:  H V Barnes; T Bledsoe
Journal:  J Clin Endocrinol Metab       Date:  1972-08       Impact factor: 5.958

5.  The pharmacokinetics of propylthiouracil.

Authors:  J Kampmann; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-11

6.  Serum propylthiouracil: determination by a direct colorimetric procedure.

Authors:  C R Ratliff; P F Gilliland; F F Hall
Journal:  Clin Chem       Date:  1972-11       Impact factor: 8.327

7.  Effect of frequency of administration on the accumulation and metabolism of (35S) propylthiouracil by the rat thyroid.

Authors:  A D Pharmakiotis; W D Alexander
Journal:  Endocrinology       Date:  1975-05       Impact factor: 4.736

8.  Reduction in extrathyroidal triiodothyronine production by propylthiouracil in man.

Authors:  M Saberi; F H Sterling; R D Utiger
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

9.  Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents.

Authors:  J Abuid; P R Larsen
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

10.  Propylthiouracil inhibits the conversion of L-thyroxine to L-triiodothyronine. An explanation of the antithyroxine effect of propylthiouracil and evidence supporting the concept that triiodothyronine is the active thyroid hormone.

Authors:  J H Oppenheimer; H L Schwartz; M I Surks
Journal:  J Clin Invest       Date:  1972-09       Impact factor: 14.808

View more
  1 in total

Review 1.  Clinical pharmacokinetics of antithyroid drugs.

Authors:  J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.